Aldeyra Therapeutics, Inc.
ALDX
$1.91
$0.021.06%
| Weiss Ratings | ALDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | ALDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ALDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.88 | |||
| Price History | ALDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -64.13% | |||
| 30-Day Total Return | -62.62% | |||
| 60-Day Total Return | -61.99% | |||
| 90-Day Total Return | -61.02% | |||
| Year to Date Total Return | -63.41% | |||
| 1-Year Total Return | -56.59% | |||
| 2-Year Total Return | -81.62% | |||
| 3-Year Total Return | -59.01% | |||
| 5-Year Total Return | -22.98% | |||
| 52-Week High % Change | -73.75% | |||
| 52-Week Low % Change | 65.79% | |||
| Price | ALDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $7.20 | |||
| 52-Week Low Price | $1.14 | |||
| 52-Week Low Price (Date) | Apr 03, 2025 | |||
| 52-Week High Price (Date) | Mar 12, 2025 | |||
| Valuation | ALDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 112.85M | |||
| Enterprise Value | 27.00M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.94 | |||
| Earnings Per Share Growth | 47.24% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 1.59 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $1.91 | |||
| Enterprise Value/EBITDA (TTM) | -0.45 | |||
| Enterprise Value/EBIT | -0.45 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | ALDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 59.58M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ALDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 781 761 4904 | |||
| Address | 131 Hartwell Avenue Lexington, MA 02421 | |||
| Website | www.aldeyra.com | |||
| Country | United States | |||
| Year Founded | 2004 | |||
| Profitability | ALDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | ALDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -29.71% | |||
| Return on Equity | -- | |||
| Income Statement | ALDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -59.87M | |||
| EBIT (TTM) | -60.12M | |||
| Net Income (TTM) | -55.85M | |||
| Net Income Avl. to Common (TTM) | -55.85M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -232.61% | |||
| EPS Diluted (TTM) | -0.94 | |||
| EPS Diluted Growth (Q YOY) | -230.39% | |||
| Balance Sheet | ALDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 101.15M | |||
| Cash Per Share (Q) | $1.70 | |||
| Total Current Assets (Q) | 104.07M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 71.00M | |||
| Current Ratio (Q) | 5.595 | |||
| Book Value Per Share (Q) | $1.19 | |||
| Total Assets (Q) | 104.61M | |||
| Total Current Liabilities (Q) | 18.60M | |||
| Total Debt (Q) | 15.30M | |||
| Total Liabilities (Q) | 33.60M | |||
| Total Common Equity (Q) | 71.00M | |||
| Cash Flow | ALDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -44.92M | |||
| Cash from Financing (TTM) | -171.40K | |||
| Net Change in Cash (TTM) | -88.30M | |||
| Levered Free Cash Flow (TTM) | -17.06M | |||
| Cash from Operations (TTM) | -43.21M | |||
